#METABOLOMICS WORKBENCH metabolic_charlie_20220511_212306 DATATRACK_ID:3244 STUDY_ID:ST002163 ANALYSIS_ID:AN003545 PROJECT_ID:PR001376
VERSION             	1
CREATED_ON             	May 13, 2022, 7:22 am
#PROJECT
PR:PROJECT_TITLE                 	Remote solid cancers rewire hepatic nitrogen metabolism via host
PR:PROJECT_TITLE                 	nicotinamide-N-methyltransferase
PR:PROJECT_SUMMARY               	Cancers disrupt host homeostasis in various manners but the identity of host
PR:PROJECT_SUMMARY               	factors underlying such disruption remains largely unknown. Here we show that
PR:PROJECT_SUMMARY               	nicotinamide-N-methyltransferase (NNMT) is a novel host factor that mediates
PR:PROJECT_SUMMARY               	metabolic dysfunction in the livers of cancer-bearing mice. Multiple solid
PR:PROJECT_SUMMARY               	cancers distantly increase expression of Nnmt and its product
PR:PROJECT_SUMMARY               	1-methylnicotinamide (MNAM) in the liver. Multi-omics analyses reveal
PR:PROJECT_SUMMARY               	suppression of the urea cycle accompanied by accumulation of amino acids, and
PR:PROJECT_SUMMARY               	enhancement of uracil biogenesis in the livers of cancer-bearing mice.
PR:PROJECT_SUMMARY               	Importantly, genetic deletion of Nnmt leads to alleviation of these metabolic
PR:PROJECT_SUMMARY               	abnormalities, and buffers cancer-dependent weight loss and reduction of the
PR:PROJECT_SUMMARY               	voluntary wheel-running activity. Our data also demonstrate that MNAM is capable
PR:PROJECT_SUMMARY               	of affecting urea cycle metabolites in the liver. These results suggest that
PR:PROJECT_SUMMARY               	cancers up-regulate the hepatic NNMT pathway to rewire liver metabolism towards
PR:PROJECT_SUMMARY               	uracil biogenesis rather than nitrogen disposal via the urea cycle, thereby
PR:PROJECT_SUMMARY               	disrupting host homeostasis.
PR:INSTITUTE                     	Tohoku University
PR:LAST_NAME                     	Kawaoka
PR:FIRST_NAME                    	Shinpei
PR:ADDRESS                       	4-1 Seiryo-cho, Sendai, Miyagi, 9808575, Japan
PR:EMAIL                         	kawaokashinpei@gmail.com
PR:PHONE                         	0227178568
#STUDY
ST:STUDY_TITLE                   	Remote solid cancers rewire hepatic nitrogen metabolism via host
ST:STUDY_TITLE                   	nicotinamide-N-methyltransferase
ST:STUDY_SUMMARY                 	Cancers disrupt host homeostasis in various manners but the identity of host
ST:STUDY_SUMMARY                 	factors underlying such disruption remains largely unknown. Here we show that
ST:STUDY_SUMMARY                 	nicotinamide-N-methyltransferase (NNMT) is a novel host factor that mediates
ST:STUDY_SUMMARY                 	metabolic dysfunction in the livers of cancer-bearing mice. Multiple solid
ST:STUDY_SUMMARY                 	cancers distantly increase expression of Nnmt and its product
ST:STUDY_SUMMARY                 	1-methylnicotinamide (MNAM) in the liver. Multi-omics analyses reveal
ST:STUDY_SUMMARY                 	suppression of the urea cycle accompanied by accumulation of amino acids, and
ST:STUDY_SUMMARY                 	enhancement of uracil biogenesis in the livers of cancer-bearing mice.
ST:STUDY_SUMMARY                 	Importantly, genetic deletion of Nnmt leads to alleviation of these metabolic
ST:STUDY_SUMMARY                 	abnormalities, and buffers cancer-dependent weight loss and reduction of the
ST:STUDY_SUMMARY                 	voluntary wheel-running activity. Our data also demonstrate that MNAM is capable
ST:STUDY_SUMMARY                 	of affecting urea cycle metabolites in the liver. These results suggest that
ST:STUDY_SUMMARY                 	cancers up-regulate the hepatic NNMT pathway to rewire liver metabolism towards
ST:STUDY_SUMMARY                 	uracil biogenesis rather than nitrogen disposal via the urea cycle, thereby
ST:STUDY_SUMMARY                 	disrupting host homeostasis. Anionic polar metabolites (i.e., organic acids,
ST:STUDY_SUMMARY                 	sugar phosphates, nucleotides,etc.) were analyzed via IC/HR/MS/MS. Cationic
ST:STUDY_SUMMARY                 	polar metabolites (i.e., amino acids, bases, nucleosides, NAM, SAM, MNAM, SAH,
ST:STUDY_SUMMARY                 	me2PY, me4PY, etc) were analyzed via PFPP-LC/HR/MS/MS.
ST:INSTITUTE                     	Tohoku University
ST:LAST_NAME                     	Kawaoka
ST:FIRST_NAME                    	Shinpei
ST:ADDRESS                       	4-1, Seiryou-machi, Aoba-ku, Sendai
ST:EMAIL                         	kawaokashinpei@gmail.com
ST:PHONE                         	0227178443
#SUBJECT
SU:SUBJECT_TYPE                  	Mammal
SU:SUBJECT_SPECIES               	Mus musculus
SU:TAXONOMY_ID                   	10090
#FACTORS
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	190428	L1	Genotype:WT | Sample group:Sham | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L1
SUBJECT_SAMPLE_FACTORS           	190428	L2	Genotype:WT | Sample group:Sham | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L2
SUBJECT_SAMPLE_FACTORS           	190428	L3	Genotype:WT | Sample group:Sham | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L3
SUBJECT_SAMPLE_FACTORS           	190428	L4	Genotype:WT | Sample group:Sham | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L4
SUBJECT_SAMPLE_FACTORS           	190428	L49	Genotype:WT | Sample group:Sham | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L49
SUBJECT_SAMPLE_FACTORS           	190428	L5	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L5
SUBJECT_SAMPLE_FACTORS           	190428	L6	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L6
SUBJECT_SAMPLE_FACTORS           	190428	L7	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L7
SUBJECT_SAMPLE_FACTORS           	190428	L8	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L8
SUBJECT_SAMPLE_FACTORS           	190428	L50	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L50
SUBJECT_SAMPLE_FACTORS           	190428	L9	Genotype:NNMT KO | Sample group:Sham | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L9
SUBJECT_SAMPLE_FACTORS           	190428	L10	Genotype:NNMT KO | Sample group:Sham | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L10
SUBJECT_SAMPLE_FACTORS           	190428	L11	Genotype:NNMT KO | Sample group:Sham | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L11
SUBJECT_SAMPLE_FACTORS           	190428	L12	Genotype:NNMT KO | Sample group:Sham | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L12
SUBJECT_SAMPLE_FACTORS           	190428	L52	Genotype:NNMT KO | Sample group:Sham | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L52
SUBJECT_SAMPLE_FACTORS           	190428	L13	Genotype:NNMT KO | Sample group:4T1 | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L13
SUBJECT_SAMPLE_FACTORS           	190428	L14	Genotype:NNMT KO | Sample group:4T1 | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L14
SUBJECT_SAMPLE_FACTORS           	190428	L15	Genotype:NNMT KO | Sample group:4T1 | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L15
SUBJECT_SAMPLE_FACTORS           	190428	L16	Genotype:NNMT KO | Sample group:4T1 | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L16
SUBJECT_SAMPLE_FACTORS           	190428	L51	Genotype:NNMT KO | Sample group:4T1 | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L51
SUBJECT_SAMPLE_FACTORS           	201215	L1_MNAM	Genotype:WT | Sample group:Sham | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L1_MNAM
SUBJECT_SAMPLE_FACTORS           	201215	L2_MNAM	Genotype:WT | Sample group:Sham | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L2_MNAM
SUBJECT_SAMPLE_FACTORS           	201215	L3_MNAM	Genotype:WT | Sample group:Sham | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L3_MNAM
SUBJECT_SAMPLE_FACTORS           	201215	L4_MNAM	Genotype:WT | Sample group:Sham | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L4_MNAM
SUBJECT_SAMPLE_FACTORS           	201215	L5_MNAM	Genotype:WT | Sample group:Sham | Sex:female | Treatment:MNAM treatment	RAW_FILE_NAME=L5_MNAM
SUBJECT_SAMPLE_FACTORS           	201215	L6_MNAM	Genotype:WT | Sample group:Sham | Sex:female | Treatment:MNAM treatment	RAW_FILE_NAME=L6_MNAM
SUBJECT_SAMPLE_FACTORS           	201215	L7_MNAM	Genotype:WT | Sample group:Sham | Sex:female | Treatment:MNAM treatment	RAW_FILE_NAME=L7_MNAM
SUBJECT_SAMPLE_FACTORS           	201215	L8_MNAM	Genotype:WT | Sample group:Sham | Sex:female | Treatment:MNAM treatment	RAW_FILE_NAME=L8_MNAM
SUBJECT_SAMPLE_FACTORS           	201215	L9_MNAM	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L9_MNAM
SUBJECT_SAMPLE_FACTORS           	201215	L10_MNAM	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L10_MNAM
SUBJECT_SAMPLE_FACTORS           	201215	L11_MNAM	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L11_MNAM
SUBJECT_SAMPLE_FACTORS           	201215	L12_MNAM	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:No treatment	RAW_FILE_NAME=L12_MNAM
SUBJECT_SAMPLE_FACTORS           	201215	L13_MNAM	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:MNAM treatment	RAW_FILE_NAME=L13_MNAM
SUBJECT_SAMPLE_FACTORS           	201215	L14_MNAM	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:MNAM treatment	RAW_FILE_NAME=L14_MNAM
SUBJECT_SAMPLE_FACTORS           	201215	L15_MNAM	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:MNAM treatment	RAW_FILE_NAME=L15_MNAM
SUBJECT_SAMPLE_FACTORS           	201215	L16_MNAM	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:MNAM treatment	RAW_FILE_NAME=L16_MNAM
SUBJECT_SAMPLE_FACTORS           	201215	L17_MNAM	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:MNAM treatment	RAW_FILE_NAME=L17_MNAM
#COLLECTION
CO:COLLECTION_SUMMARY            	Mouse livers were crushed in liquid-nitrogen and homogenized.
CO:SAMPLE_TYPE                   	Liver
#TREATMENT
TR:TREATMENT_SUMMARY             	Daily 250 mg/kg MNAM injection for 12 days in the absence (sham) and presence
TR:TREATMENT_SUMMARY             	(4T1cancers).
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	Metabolites were extracted from the frozen livers (approximately 5 mg) using the
SP:SAMPLEPREP_SUMMARY            	Bligh and Dyer’s method with some modifications. Briefly, each sample was
SP:SAMPLEPREP_SUMMARY            	mixed with 1 mL of cold methanol containing 10-camphorsulfonic acid (1.5 nmol)
SP:SAMPLEPREP_SUMMARY            	and piperazine-1,4-bis (2-ethanesulfonic acid) (PIPES, 1.5 nmol) as internal
SP:SAMPLEPREP_SUMMARY            	standards for mass spectrometry-based metabolomic analysis. The samples were
SP:SAMPLEPREP_SUMMARY            	vigorously mixed by vortexing for 1 min followed by 5 min of sonication. The
SP:SAMPLEPREP_SUMMARY            	extracts were then centrifuged at 16,000 × g for 5 min at 4 °C, and the
SP:SAMPLEPREP_SUMMARY            	resultant supernatant (400 uL) was collected. After mixing 400 uL of supernatant
SP:SAMPLEPREP_SUMMARY            	with 400 uL of chloroform and 320 uL of water, the aqueous and organic layers
SP:SAMPLEPREP_SUMMARY            	were separated by vortexing and subsequent centrifugation at 16,000 × g and 4
SP:SAMPLEPREP_SUMMARY            	°C for 5 min. The aqueous (upper) layer (500 uL) was transferred into a clean
SP:SAMPLEPREP_SUMMARY            	tube. After the aqueous layer extracts were evaporated under vacuum, the dried
SP:SAMPLEPREP_SUMMARY            	extracts were stored at −80 °C until the analysis of hydrophilic metabolites.
SP:SAMPLEPREP_SUMMARY            	Prior to analysis, the dried aqueous layer was reconstituted in 50 uL of water.
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_SUMMARY        	Cationic polar metabolites (i.e., amino acids, bases, nucleosides, NAM, SAM,
CH:CHROMATOGRAPHY_SUMMARY        	MNAM, SAH, me2PY, me4PY, etc) were analyzed via PFPP-LC/HRMS/MS.
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Shimadzu Nexera X2
CH:COLUMN_NAME                   	Discovery HS (2.1 mm i.d. × 150 mm, 3 um particle size, Merck)
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
AN:LABORATORY_NAME               	Bamba lab.
AN:OPERATOR_NAME                 	Masatomo Takahashi
#MS
MS:INSTRUMENT_NAME               	Thermo Q Exactive Orbitrap
MS:INSTRUMENT_TYPE               	Orbitrap
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	POSITIVE
MS:MS_COMMENTS                   	-
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS	peak area
MS_METABOLITE_DATA_START
Samples	L1	L2	L3	L4	L49	L5	L6	L7	L8	L50	L9	L10	L11	L12	L52	L13	L14	L15	L16	L51	L1_MNAM	L2_MNAM	L3_MNAM	L4_MNAM	L5_MNAM	L6_MNAM	L7_MNAM	L8_MNAM	L9_MNAM	L10_MNAM	L11_MNAM	L12_MNAM	L13_MNAM	L14_MNAM	L15_MNAM	L16_MNAM	L17_MNAM
Factors	Genotype:WT | Sample group:Sham | Sex:female | Treatment:No treatment	Genotype:WT | Sample group:Sham | Sex:female | Treatment:No treatment	Genotype:WT | Sample group:Sham | Sex:female | Treatment:No treatment	Genotype:WT | Sample group:Sham | Sex:female | Treatment:No treatment	Genotype:WT | Sample group:Sham | Sex:female | Treatment:No treatment	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:No treatment	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:No treatment	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:No treatment	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:No treatment	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:No treatment	Genotype:NNMT KO | Sample group:Sham | Sex:female | Treatment:No treatment	Genotype:NNMT KO | Sample group:Sham | Sex:female | Treatment:No treatment	Genotype:NNMT KO | Sample group:Sham | Sex:female | Treatment:No treatment	Genotype:NNMT KO | Sample group:Sham | Sex:female | Treatment:No treatment	Genotype:NNMT KO | Sample group:Sham | Sex:female | Treatment:No treatment	Genotype:NNMT KO | Sample group:4T1 | Sex:female | Treatment:No treatment	Genotype:NNMT KO | Sample group:4T1 | Sex:female | Treatment:No treatment	Genotype:NNMT KO | Sample group:4T1 | Sex:female | Treatment:No treatment	Genotype:NNMT KO | Sample group:4T1 | Sex:female | Treatment:No treatment	Genotype:NNMT KO | Sample group:4T1 | Sex:female | Treatment:No treatment	Genotype:WT | Sample group:Sham | Sex:female | Treatment:No treatment	Genotype:WT | Sample group:Sham | Sex:female | Treatment:No treatment	Genotype:WT | Sample group:Sham | Sex:female | Treatment:No treatment	Genotype:WT | Sample group:Sham | Sex:female | Treatment:No treatment	Genotype:WT | Sample group:Sham | Sex:female | Treatment:MNAM treatment	Genotype:WT | Sample group:Sham | Sex:female | Treatment:MNAM treatment	Genotype:WT | Sample group:Sham | Sex:female | Treatment:MNAM treatment	Genotype:WT | Sample group:Sham | Sex:female | Treatment:MNAM treatment	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:No treatment	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:No treatment	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:No treatment	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:No treatment	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:MNAM treatment	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:MNAM treatment	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:MNAM treatment	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:MNAM treatment	Genotype:WT | Sample group:4T1 | Sex:female | Treatment:MNAM treatment
10-Camphorsulfonic acid (IS)	2.E+07	2.E+07	2.E+07	2.E+07	2.E+07	1.E+07	1.E+07	2.E+07	1.E+07	1.E+07	1.E+07	1.E+07	2.E+07	2.E+07	2.E+07	2.E+07	2.E+07	2.E+07	2.E+07	1.E+07	4.E+07	5.E+07	4.E+07	4.E+07	3.E+07	3.E+07	3.E+07	4.E+07	4.E+07	3.E+07	3.E+07	3.E+07	3.E+07	3.E+07	3.E+07	3.E+07	3.E+07
PIPES (IS)	5.E+07	6.E+07	4.E+07	5.E+07	5.E+07	3.E+07	3.E+07	4.E+07	3.E+07	3.E+07	3.E+07	3.E+07	4.E+07	4.E+07	3.E+07	5.E+07	5.E+07	5.E+07	4.E+07	3.E+07	8.E+07	9.E+07	9.E+07	8.E+07	7.E+07	8.E+07	6.E+07	8.E+07	8.E+07	7.E+07	7.E+07	6.E+07	6.E+07	6.E+07	6.E+07	6.E+07	6.E+07
NAD	3.E+07	3.E+07	2.E+07	3.E+07	3.E+07	1.E+07	2.E+07	2.E+07	1.E+07	1.E+07	2.E+07	3.E+07	4.E+07	3.E+07	3.E+07	2.E+07	2.E+07	2.E+07	1.E+07	2.E+07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Suc	5.E+07	5.E+07	2.E+07	5.E+07	6.E+07	3.E+07	3.E+07	4.E+07	5.E+07	4.E+07	1.E+07	4.E+07	4.E+07	4.E+07	4.E+07	4.E+07	5.E+07	8.E+07	4.E+07	4.E+07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Adenine	3.E+07	4.E+07	3.E+07	3.E+07	3.E+07	2.E+07	2.E+07	3.E+07	2.E+07	2.E+07	2.E+07	2.E+07	3.E+07	3.E+07	3.E+07	3.E+07	3.E+07	3.E+07	2.E+07	2.E+07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Adenosine	1.E+08	1.E+08	9.E+07	8.E+07	1.E+08	7.E+07	1.E+08	2.E+08	8.E+07	1.E+08	8.E+07	7.E+07	1.E+08	1.E+08	9.E+07	1.E+08	2.E+08	3.E+08	2.E+08	1.E+08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Beta-Ala	2.E+07	2.E+07	1.E+07	2.E+07	3.E+07	2.E+07	3.E+07	4.E+07	3.E+07	3.E+07	1.E+07	3.E+07	4.E+07	3.E+07	2.E+07	5.E+07	4.E+07	6.E+07	4.E+07	3.E+07	2.E+08	2.E+08	2.E+08	3.E+08	2.E+08	2.E+08	2.E+08	2.E+08	3.E+08	2.E+08	3.E+08	2.E+08	2.E+08	2.E+08	2.E+08	3.E+08	3.E+08
Betaine	2.E+08	1.E+08	1.E+08	1.E+08	3.E+08	2.E+08	3.E+08	8.E+08	3.E+08	2.E+08	4.E+08	1.E+09	6.E+08	6.E+08	3.E+08	8.E+08	5.E+08	7.E+08	2.E+08	2.E+08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Carnitine	8.E+08	7.E+08	4.E+08	5.E+08	5.E+08	4.E+08	6.E+08	7.E+08	4.E+08	5.E+08	7.E+08	8.E+08	8.E+08	8.E+08	5.E+08	8.E+08	7.E+08	8.E+08	6.E+08	4.E+08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Carnosine	2.E+06	3.E+06	7.E+05	1.E+06	1.E+06	4.E+05	4.E+05	4.E+05	5.E+05	1.E+06	1.E+06	6.E+05	1.E+06	2.E+06	1.E+06	1.E+06	2.E+06	8.E+05	5.E+05	1.E+06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Choline	7.E+08	7.E+08	6.E+08	5.E+08	6.E+08	6.E+08	8.E+08	9.E+08	6.E+08	7.E+08	5.E+08	5.E+08	6.E+08	8.E+08	5.E+08	1.E+09	1.E+09	1.E+09	9.E+08	9.E+08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Creatine	5.E+08	5.E+08	3.E+08	4.E+08	4.E+08	3.E+08	4.E+08	4.E+08	4.E+08	4.E+08	3.E+08	2.E+08	4.E+08	4.E+08	3.E+08	5.E+08	5.E+08	6.E+08	5.E+08	4.E+08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Creatinine	4.E+07	4.E+07	2.E+07	5.E+07	3.E+07	3.E+07	3.E+07	5.E+07	3.E+07	2.E+07	2.E+07	3.E+07	4.E+07	4.E+07	3.E+07	5.E+07	4.E+07	6.E+07	3.E+07	3.E+07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cytidine	1.E+06	1.E+06	8.E+05	1.E+06	9.E+05	2.E+06	3.E+06	5.E+06	2.E+06	2.E+06	9.E+05	8.E+05	1.E+06	1.E+06	9.E+05	3.E+06	4.E+06	6.E+06	4.E+06	2.E+06	6.E+06	2.E+07	1.E+07	6.E+06	4.E+06	5.E+06	1.E+07	6.E+06	1.E+07	7.E+06	7.E+06	7.E+06	6.E+06	6.E+06	6.E+06	8.E+06	7.E+06
Cytosine	3.E+06	4.E+06	2.E+06	4.E+06	2.E+06	2.E+06	2.E+06	3.E+06	1.E+06	2.E+06	2.E+06	3.E+06	3.E+06	2.E+06	2.E+06	3.E+06	3.E+06	3.E+06	2.E+06	2.E+06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
GABA	1.E+07	1.E+07	1.E+07	1.E+07	1.E+07	5.E+06	4.E+06	8.E+06	8.E+06	7.E+06	7.E+06	1.E+07	2.E+07	1.E+07	1.E+07	1.E+07	9.E+06	1.E+07	7.E+06	7.E+06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gly	6.E+07	7.E+07	3.E+07	4.E+07	8.E+07	2.E+07	4.E+07	5.E+07	3.E+07	5.E+07	4.E+07	5.E+07	8.E+07	8.E+07	5.E+07	7.E+07	8.E+07	7.E+07	5.E+07	4.E+07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Guanine	7.E+05	2.E+06	5.E+05	6.E+05	9.E+05	5.E+05	5.E+05	9.E+05	5.E+05	7.E+05	7.E+05	8.E+05	1.E+06	9.E+05	8.E+05	1.E+06	8.E+05	9.E+05	6.E+05	8.E+05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Guanosine	7.E+06	8.E+06	4.E+06	4.E+06	5.E+06	2.E+06	5.E+06	1.E+07	2.E+06	4.E+06	5.E+06	4.E+06	6.E+06	7.E+06	6.E+06	8.E+06	1.E+07	2.E+07	1.E+07	6.E+06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4-Hydroxy-Pro	1.E+07	1.E+07	6.E+06	1.E+07	3.E+07	3.E+07	2.E+07	8.E+07	3.E+07	2.E+07	2.E+07	7.E+07	4.E+07	4.E+07	1.E+07	7.E+07	4.E+07	9.E+07	3.E+07	2.E+07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Hypoxanthine	2.E+08	2.E+08	1.E+08	2.E+08	2.E+08	1.E+08	1.E+08	2.E+08	1.E+08	2.E+08	2.E+08	1.E+08	2.E+08	2.E+08	2.E+08	2.E+08	2.E+08	2.E+08	1.E+08	2.E+08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Ala	3.E+08	5.E+08	2.E+08	3.E+08	5.E+08	2.E+08	2.E+08	3.E+08	2.E+08	3.E+08	2.E+08	4.E+08	5.E+08	4.E+08	3.E+08	5.E+08	4.E+08	5.E+08	3.E+08	2.E+08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Arg	7.E+06	1.E+07	6.E+06	1.E+07	1.E+07	2.E+07	1.E+07	9.E+06	2.E+07	2.E+07	7.E+06	1.E+07	1.E+07	9.E+06	1.E+07	2.E+07	2.E+07	2.E+07	1.E+07	2.E+07	8.E+06	9.E+06	1.E+07	1.E+07	2.E+07	1.E+07	1.E+07	1.E+07	2.E+07	1.E+07	2.E+07	1.E+07	1.E+07	1.E+07	1.E+07	3.E+07	1.E+07
Asn	3.E+07	3.E+07	2.E+07	3.E+07	3.E+07	3.E+07	4.E+07	3.E+07	3.E+07	5.E+07	2.E+07	3.E+07	3.E+07	3.E+07	4.E+07	4.E+07	6.E+07	4.E+07	4.E+07	4.E+07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Asp	2.E+08	1.E+08	7.E+07	1.E+08	1.E+08	1.E+08	1.E+08	1.E+08	1.E+08	2.E+08	7.E+07	9.E+07	1.E+08	1.E+08	1.E+08	2.E+08	2.E+08	2.E+08	2.E+08	1.E+08	2.E+08	3.E+08	5.E+08	3.E+08	3.E+08	2.E+08	4.E+08	3.E+08	6.E+08	5.E+08	5.E+08	5.E+08	3.E+08	4.E+08	3.E+08	5.E+08	5.E+08
Citrulline	2.E+07	2.E+07	1.E+07	1.E+07	2.E+07	2.E+07	2.E+07	3.E+07	3.E+07	2.E+07	1.E+07	3.E+07	2.E+07	3.E+07	2.E+07	4.E+07	3.E+07	4.E+07	3.E+07	1.E+07	5.E+07	7.E+07	7.E+07	9.E+07	5.E+07	4.E+07	8.E+07	8.E+07	7.E+07	6.E+07	7.E+07	7.E+07	4.E+07	5.E+07	4.E+07	4.E+07	5.E+07
Cys	1.E+06	3.E+06	7.E+05	1.E+06	2.E+06	2.E+06	3.E+06	3.E+06	4.E+06	3.E+06	1.E+06	2.E+06	2.E+06	4.E+06	2.E+06	6.E+06	7.E+06	6.E+06	3.E+06	4.E+06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Glu	8.E+08	5.E+08	5.E+08	8.E+08	8.E+08	5.E+08	6.E+08	5.E+08	6.E+08	8.E+08	4.E+08	8.E+08	1.E+09	1.E+09	9.E+08	8.E+08	9.E+08	9.E+08	9.E+08	6.E+08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gln	2.E+09	2.E+09	1.E+09	2.E+09	2.E+09	8.E+08	1.E+09	1.E+09	7.E+08	2.E+09	9.E+08	1.E+09	1.E+09	1.E+09	2.E+09	1.E+09	2.E+09	1.E+09	1.E+09	2.E+09	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
His	5.E+08	5.E+08	3.E+08	4.E+08	6.E+08	2.E+08	3.E+08	4.E+08	3.E+08	4.E+08	3.E+08	4.E+08	5.E+08	5.E+08	5.E+08	5.E+08	5.E+08	4.E+08	3.E+08	4.E+08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
HomoSer	5.E+07	6.E+07	4.E+07	5.E+07	8.E+07	6.E+07	7.E+07	8.E+07	8.E+07	1.E+08	5.E+07	9.E+07	9.E+07	1.E+08	7.E+07	1.E+08	1.E+08	1.E+08	9.E+07	8.E+07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Ile	1.E+08	2.E+08	1.E+08	1.E+08	2.E+08	1.E+08	1.E+08	2.E+08	2.E+08	2.E+08	1.E+08	2.E+08	2.E+08	2.E+08	2.E+08	3.E+08	3.E+08	3.E+08	2.E+08	2.E+08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Leu	3.E+08	3.E+08	2.E+08	3.E+08	4.E+08	2.E+08	3.E+08	3.E+08	3.E+08	4.E+08	2.E+08	3.E+08	4.E+08	4.E+08	4.E+08	5.E+08	5.E+08	6.E+08	3.E+08	3.E+08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lys	2.E+08	2.E+08	1.E+08	1.E+08	2.E+08	2.E+08	2.E+08	3.E+08	3.E+08	3.E+08	2.E+08	3.E+08	2.E+08	2.E+08	2.E+08	4.E+08	4.E+08	4.E+08	2.E+08	3.E+08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Met	2.E+07	3.E+07	1.E+07	2.E+07	2.E+07	2.E+07	3.E+07	3.E+07	3.E+07	4.E+07	2.E+07	2.E+07	3.E+07	3.E+07	3.E+07	4.E+07	5.E+07	4.E+07	3.E+07	3.E+07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Orn	2.E+07	2.E+07	2.E+07	2.E+07	4.E+07	6.E+07	3.E+07	4.E+07	1.E+08	4.E+07	3.E+07	1.E+08	4.E+07	4.E+07	3.E+07	7.E+07	4.E+07	8.E+07	4.E+07	4.E+07	1.E+08	1.E+08	1.E+08	1.E+08	1.E+08	1.E+08	2.E+08	1.E+08	2.E+08	2.E+08	2.E+08	2.E+08	2.E+08	2.E+08	2.E+08	3.E+08	2.E+08
Phe	2.E+08	2.E+08	1.E+08	2.E+08	2.E+08	2.E+08	2.E+08	3.E+08	2.E+08	3.E+08	1.E+08	2.E+08	2.E+08	2.E+08	2.E+08	4.E+08	4.E+08	4.E+08	3.E+08	2.E+08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pro	1.E+08	1.E+08	9.E+07	9.E+07	2.E+08	2.E+08	1.E+08	2.E+08	3.E+08	2.E+08	9.E+07	3.E+08	2.E+08	2.E+08	1.E+08	3.E+08	2.E+08	4.E+08	2.E+08	2.E+08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Trp	7.E+07	8.E+07	5.E+07	6.E+07	7.E+07	5.E+07	6.E+07	6.E+07	6.E+07	8.E+07	4.E+07	7.E+07	7.E+07	8.E+07	6.E+07	1.E+08	1.E+08	1.E+08	6.E+07	8.E+07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tyr	6.E+07	9.E+07	5.E+07	7.E+07	7.E+07	6.E+07	7.E+07	6.E+07	7.E+07	1.E+08	4.E+07	8.E+07	8.E+07	6.E+07	8.E+07	1.E+08	1.E+08	1.E+08	9.E+07	9.E+07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Val	1.E+08	2.E+08	9.E+07	1.E+08	2.E+08	1.E+08	1.E+08	2.E+08	2.E+08	2.E+08	1.E+08	2.E+08	2.E+08	2.E+08	2.E+08	3.E+08	3.E+08	3.E+08	2.E+08	2.E+08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
DMG	6.E+07	4.E+07	4.E+07	5.E+07	1.E+08	7.E+07	6.E+07	1.E+08	9.E+07	4.E+07	8.E+07	1.E+08	2.E+08	1.E+08	6.E+07	2.E+08	8.E+07	2.E+08	8.E+07	3.E+07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
GSSG	8.E+07	6.E+07	4.E+07	5.E+07	5.E+07	1.E+07	2.E+07	3.E+07	1.E+07	3.E+07	3.E+07	4.E+07	6.E+07	9.E+07	3.E+07	5.E+07	6.E+07	5.E+07	4.E+07	4.E+07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
GSH	2.E+09	3.E+09	1.E+09	2.E+09	2.E+09	1.E+09	1.E+09	1.E+09	1.E+09	2.E+09	2.E+09	2.E+09	3.E+09	2.E+09	2.E+09	2.E+09	2.E+09	2.E+09	2.E+09	2.E+09	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
SAH	2.E+07	2.E+07	1.E+07	2.E+07	2.E+07	9.E+06	8.E+06	1.E+07	1.E+07	7.E+06	2.E+07	3.E+07	3.E+07	3.E+07	1.E+07	1.E+07	1.E+07	2.E+07	9.E+06	9.E+06	2.E+07	6.E+07	5.E+07	4.E+07	2.E+07	2.E+07	4.E+07	3.E+07	1.E+07	1.E+07	2.E+07	2.E+07	1.E+07	1.E+07	1.E+07	1.E+07	1.E+07
SAM	8.E+06	1.E+07	7.E+06	9.E+06	5.E+06	8.E+06	9.E+06	8.E+06	7.E+06	1.E+07	6.E+06	6.E+06	3.E+06	6.E+06	1.E+07	1.E+07	2.E+07	1.E+07	1.E+07	1.E+07	1.E+06	7.E+05	2.E+05	3.E+06	3.E+06	3.E+06	4.E+06	3.E+06	3.E+06	2.E+06	3.E+06	2.E+06	2.E+06	3.E+06	1.E+06	3.E+06	1.E+06
Uracil	4.E+07	3.E+07	2.E+07	2.E+07	3.E+07	3.E+07	4.E+07	3.E+07	3.E+07	3.E+07	2.E+07	3.E+07	4.E+07	3.E+07	3.E+07	3.E+07	4.E+07	5.E+07	3.E+07	3.E+07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Uridine	1.E+07	1.E+07	7.E+06	7.E+06	8.E+06	7.E+06	1.E+07	1.E+07	8.E+06	9.E+06	6.E+06	8.E+06	1.E+07	8.E+06	9.E+06	8.E+06	1.E+07	1.E+07	8.E+06	8.E+06	3.E+08	4.E+08	3.E+08	3.E+08	3.E+08	3.E+08	3.E+08	3.E+08	3.E+08	3.E+08	3.E+08	2.E+08	3.E+08	2.E+08	2.E+08	2.E+08	2.E+08
L-Cystathionine	3.E+06	4.E+06	2.E+06	4.E+06	1.E+07	1.E+07	4.E+06	1.E+07	2.E+07	5.E+06	7.E+06	3.E+07	1.E+07	1.E+07	3.E+06	3.E+07	8.E+06	3.E+07	9.E+06	6.E+06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gamma-Glu-Cys	9.E+06	1.E+07	6.E+06	1.E+07	8.E+06	7.E+06	8.E+06	6.E+06	8.E+06	1.E+07	5.E+06	1.E+07	1.E+07	1.E+07	1.E+07	8.E+06	1.E+07	1.E+07	9.E+06	8.E+06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
5-Hydroxy-Lys	6.E+05	5.E+05	5.E+05	4.E+05	8.E+05	1.E+06	1.E+06	9.E+05	1.E+06	1.E+06	6.E+05	7.E+05	6.E+05	6.E+05	8.E+05	9.E+05	1.E+06	1.E+06	9.E+05	1.E+06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Histamine	3.E+06	1.E+07	9.E+05	2.E+06	3.E+05	1.E+07	1.E+07	1.E+07	3.E+05	3.E+06	1.E+06	5.E+05	6.E+05	5.E+05	8.E+05	1.E+07	9.E+06	1.E+07	1.E+07	6.E+05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Xanthine	5.E+07	6.E+07	3.E+07	4.E+07	4.E+07	3.E+07	4.E+07	4.E+07	3.E+07	6.E+07	4.E+07	3.E+07	5.E+07	5.E+07	5.E+07	4.E+07	5.E+07	4.E+07	4.E+07	6.E+07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deoxycytidine	1.E+05	9.E+04	4.E+04	8.E+04	2.E+04	9.E+05	1.E+06	9.E+05	1.E+06	6.E+05	3.E+04	5.E+04	4.E+04	4.E+04	4.E+04	1.E+06	1.E+06	1.E+06	1.E+06	5.E+05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Kynurenine	1.E+05	8.E+05	1.E+05	2.E+05	6.E+05	7.E+05	5.E+05	4.E+05	1.E+06	5.E+05	2.E+05	2.E+06	7.E+05	7.E+05	3.E+05	8.E+05	7.E+05	2.E+06	5.E+05	4.E+05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Trigonelline	2.E+07	2.E+07	2.E+07	3.E+07	4.E+07	4.E+07	4.E+07	1.E+08	4.E+07	4.E+07	5.E+07	8.E+07	7.E+07	1.E+08	4.E+07	1.E+08	1.E+08	1.E+08	4.E+07	3.E+07	1.E+08	8.E+07	1.E+08	6.E+07	1.E+08	6.E+07	8.E+07	1.E+08	9.E+07	1.E+08	9.E+07	5.E+07	2.E+08	2.E+08	2.E+08	6.E+07	2.E+08
Phosphocholine	1.E+09	7.E+08	6.E+08	5.E+08	1.E+09	8.E+08	1.E+09	2.E+09	1.E+09	7.E+08	1.E+09	1.E+09	1.E+09	1.E+09	7.E+08	2.E+09	2.E+09	2.E+09	1.E+09	8.E+08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Beta-Glu	2.E+07	1.E+07	7.E+06	9.E+06	1.E+07	4.E+06	8.E+06	2.E+07	5.E+06	6.E+06	4.E+06	1.E+07	1.E+07	1.E+07	1.E+07	8.E+06	6.E+06	9.E+06	8.E+06	8.E+06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Glyceraldehyde	2.E+06	2.E+06	1.E+06	1.E+06	1.E+06	6.E+05	8.E+05	6.E+05	6.E+05	9.E+05	1.E+06	9.E+05	2.E+06	1.E+06	1.E+06	6.E+05	8.E+05	5.E+05	8.E+05	1.E+06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Hypotaurine	3.E+07	4.E+07	2.E+07	3.E+07	6.E+07	4.E+07	3.E+07	8.E+07	7.E+07	4.E+07	4.E+07	1.E+08	7.E+07	9.E+07	3.E+07	7.E+07	4.E+07	1.E+08	4.E+07	4.E+07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inosine	1.E+08	1.E+08	8.E+07	8.E+07	9.E+07	4.E+07	6.E+07	6.E+07	4.E+07	9.E+07	9.E+07	6.E+07	1.E+08	1.E+08	1.E+08	7.E+07	7.E+07	6.E+07	6.E+07	1.E+08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
MSO	1.E+06	2.E+06	1.E+06	1.E+06	2.E+06	2.E+06	2.E+06	3.E+06	3.E+06	2.E+06	1.E+06	5.E+06	2.E+06	2.E+06	1.E+06	3.E+06	3.E+06	4.E+06	2.E+06	1.E+06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Succinic anhydride	8.E+06	1.E+07	5.E+06	1.E+07	2.E+07	6.E+06	6.E+06	8.E+06	1.E+07	1.E+07	3.E+06	7.E+06	8.E+06	9.E+06	1.E+07	9.E+06	1.E+07	2.E+07	9.E+06	1.E+07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gamma-Glunolactone	8.E+06	7.E+06	4.E+06	5.E+06	6.E+06	3.E+06	4.E+06	5.E+06	3.E+06	4.E+06	5.E+06	5.E+06	8.E+06	8.E+06	5.E+06	5.E+06	6.E+06	5.E+06	4.E+06	4.E+06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NMN	3.E+05	2.E+05	3.E+05	2.E+05	3.E+05	1.E+05	2.E+05	2.E+05	1.E+05	2.E+05	3.E+05	3.E+05	4.E+05	4.E+05	4.E+05	3.E+05	1.E+05	2.E+05	2.E+05	2.E+05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Trimethyl-Lys	8.E+06	8.E+06	5.E+06	5.E+06	5.E+06	5.E+06	7.E+06	8.E+06	8.E+06	6.E+06	3.E+06	6.E+06	4.E+06	5.E+06	6.E+06	8.E+06	1.E+07	9.E+06	8.E+06	5.E+06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Argininosuccinate	3.E+06	4.E+06	2.E+06	3.E+06	3.E+06	2.E+06	2.E+06	2.E+06	2.E+06	3.E+06	2.E+06	4.E+06	4.E+06	4.E+06	3.E+06	5.E+06	4.E+06	5.E+06	3.E+06	3.E+06	6.E+06	4.E+06	8.E+06	9.E+06	9.E+06	1.E+07	9.E+06	9.E+06	1.E+07	1.E+07	1.E+07	1.E+07	6.E+06	1.E+07	7.E+06	2.E+07	1.E+07
Pyridoxamine	3.E+05	2.E+05	2.E+05	2.E+05	2.E+05	2.E+05	1.E+06	5.E+06	2.E+05	3.E+05	1.E+05	9.E+04	2.E+05	7.E+05	1.E+05	2.E+06	4.E+06	1.E+07	5.E+06	7.E+05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
1-Methyl-His	3.E+07	2.E+07	1.E+07	2.E+07	3.E+07	2.E+07	2.E+07	3.E+07	2.E+07	2.E+07	1.E+07	2.E+07	3.E+07	2.E+07	2.E+07	3.E+07	5.E+07	5.E+07	4.E+07	2.E+07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Xanthosine	1.E+07	1.E+07	8.E+06	8.E+06	9.E+06	3.E+06	6.E+06	4.E+06	3.E+06	1.E+07	7.E+06	5.E+06	1.E+07	9.E+06	9.E+06	5.E+06	1.E+07	4.E+06	3.E+06	1.E+07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acetylcarnitine	6.E+08	5.E+08	5.E+08	6.E+08	7.E+08	4.E+08	5.E+08	7.E+08	5.E+08	5.E+08	4.E+08	8.E+08	7.E+08	8.E+08	5.E+08	8.E+08	8.E+08	8.E+08	5.E+08	5.E+08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Kynurenic acid	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pyridoxal	1.E+06	1.E+06	7.E+05	1.E+06	1.E+06	1.E+06	2.E+06	3.E+06	9.E+05	1.E+06	7.E+05	6.E+05	1.E+06	1.E+06	9.E+05	2.E+06	2.E+06	5.E+06	3.E+06	9.E+05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Homocitrulline	3.E+06	3.E+06	2.E+06	2.E+06	3.E+06	2.E+06	2.E+06	3.E+06	1.E+06	2.E+06	2.E+06	2.E+06	3.E+06	3.E+06	3.E+06	3.E+06	4.E+06	4.E+06	2.E+06	2.E+06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Glycerophosphocholine	6.E+08	9.E+08	5.E+08	4.E+08	6.E+08	3.E+08	4.E+08	3.E+08	3.E+08	7.E+08	4.E+08	5.E+08	7.E+08	6.E+08	4.E+08	7.E+08	7.E+08	6.E+08	6.E+08	7.E+08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Xanthurenic acid	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
N-Acetyl-ornithine	2.E+05	2.E+05	1.E+05	2.E+05	4.E+05	3.E+05	2.E+05	7.E+05	4.E+05	2.E+05	2.E+05	8.E+05	4.E+05	6.E+05	2.E+05	5.E+05	4.E+05	8.E+05	3.E+05	2.E+05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Saccharopine	2.E+06	1.E+06	1.E+06	2.E+06	5.E+06	3.E+06	4.E+05	2.E+06	7.E+06	1.E+06	3.E+06	1.E+07	8.E+06	7.E+06	2.E+06	5.E+06	2.E+06	7.E+06	2.E+06	2.E+06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
L-Anserine	5.E+05	5.E+05	3.E+05	3.E+05	4.E+05	3.E+05	4.E+05	8.E+05	3.E+05	4.E+05	2.E+05	3.E+05	4.E+05	5.E+05	3.E+05	6.E+05	7.E+05	6.E+05	4.E+05	4.E+05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
N-Acetyl-Lys	2.E+06	2.E+06	8.E+05	1.E+06	2.E+06	9.E+05	1.E+06	2.E+06	1.E+06	1.E+06	1.E+06	2.E+06	2.E+06	2.E+06	2.E+06	2.E+06	2.E+06	3.E+06	1.E+06	1.E+06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3-Hydroxyanthranilic acid	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gly-Gly	2.E+06	2.E+06	1.E+06	1.E+06	2.E+06	2.E+06	3.E+06	2.E+06	2.E+06	3.E+06	2.E+06	2.E+06	2.E+06	2.E+06	3.E+06	3.E+06	3.E+06	3.E+06	2.E+06	3.E+06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Bicine	5.E+05	5.E+05	2.E+05	2.E+05	4.E+05	2.E+05	9.E+04	4.E+05	2.E+05	2.E+05	3.E+05	3.E+05	4.E+05	4.E+05	4.E+05	4.E+05	5.E+05	5.E+05	4.E+05	7.E+05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O-Phosphoethanolamine	5.E+07	6.E+07	3.E+07	4.E+07	6.E+07	8.E+07	9.E+07	1.E+08	1.E+08	1.E+08	3.E+07	3.E+07	5.E+07	6.E+07	4.E+07	1.E+08	1.E+08	1.E+08	1.E+08	1.E+08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
MNAM	1.E+07	1.E+07	8.E+06	1.E+07	1.E+07	2.E+07	3.E+07	4.E+07	2.E+07	2.E+07	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	3.E+07	3.E+07	3.E+07	3.E+07	1.E+08	6.E+07	8.E+07	8.E+07	6.E+07	5.E+07	4.E+07	4.E+07	1.E+08	9.E+07	8.E+07	8.E+07	8.E+07
NAM	1.E+09	1.E+09	5.E+08	7.E+08	8.E+08	6.E+08	7.E+08	8.E+08	6.E+08	7.E+08	8.E+08	8.E+08	1.E+09	9.E+08	9.E+08	1.E+09	9.E+08	1.E+09	8.E+08	8.E+08	4.E+09	5.E+09	4.E+09	4.E+09	4.E+09	4.E+09	5.E+09	4.E+09	3.E+09	3.E+09	3.E+09	3.E+09	3.E+09	2.E+09	2.E+09	2.E+09	2.E+09
NAM ribose	6.E+05	8.E+05	9.E+05	1.E+06	5.E+05	2.E+05	6.E+05	1.E+05	3.E+05	1.E+06	4.E+05	3.E+05	5.E+05	2.E+05	2.E+06	1.E+05	2.E+05	2.E+05	8.E+04	5.E+05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2-py	4.E+06	4.E+06	2.E+06	3.E+06	2.E+06	2.E+06	4.E+06	6.E+06	3.E+06	2.E+06	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4-py	7.E+06	6.E+06	4.E+06	6.E+06	3.E+06	4.E+06	7.E+06	1.E+07	5.E+06	4.E+06	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	0.E+00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
N-Formylkynurenine	1.E+05	9.E+04	8.E+04	9.E+04	1.E+05	2.E+04	4.E+04	9.E+04	5.E+04	5.E+04	7.E+04	2.E+05	2.E+05	3.E+05	2.E+05	8.E+04	2.E+05	1.E+05	6.E+04	8.E+04	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name
10-Camphorsulfonic acid (IS)
PIPES (IS)
NAD
Suc
Adenine
Adenosine
Beta-Ala
Betaine
Carnitine
Carnosine
Choline
Creatine
Creatinine
Cytidine
Cytosine
GABA
Gly
Guanine
Guanosine
4-Hydroxy-Pro
Hypoxanthine
Ala
Arg
Asn
Asp
Citrulline
Cys
Glu
Gln
His
HomoSer
Ile
Leu
Lys
Met
Orn
Phe
Pro
Trp
Tyr
Val
DMG
GSSG
GSH
SAH
SAM
Uracil
Uridine
L-Cystathionine
Gamma-Glu-Cys
5-Hydroxy-Lys
Histamine
Xanthine
Deoxycytidine
Kynurenine
Trigonelline
Phosphocholine
Beta-Glu
Glyceraldehyde
Hypotaurine
Inosine
MSO
Succinic anhydride
Gamma-Glunolactone
NMN
Trimethyl-Lys
Argininosuccinate
Pyridoxamine
1-Methyl-His
Xanthosine
Acetylcarnitine
Kynurenic acid
Pyridoxal
Homocitrulline
Glycerophosphocholine
Xanthurenic acid
N-Acetyl-ornithine
Saccharopine
L-Anserine
N-Acetyl-Lys
3-Hydroxyanthranilic acid
Gly-Gly
Bicine
O-Phosphoethanolamine
MNAM
NAM
NAM ribose
2-py
4-py
N-Formylkynurenine
METABOLITES_END
#END